2020 Preliminary Program

PRELIMINARY PROGRAM 

Working titles/topics shown. Final titles and speakers will follow


EDUCATIONAL SESSIONS
Tuesday, December 8, 2020

Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.

Special Topics in ER+ Breast Cancer

Early stage breast cancer (neoadjuvant therapy, low ER, extended therapy)
Metastatic breast cancer (role of single agent therapy, CDK 4/6, subtypes, overcoming resistance)
Mechanisms of resistance (emerging/basic) 

New Frontiers in Immunotherapy
Moderator: Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Novel biomarkers in immune therapy response
Lajos Pusztai, MD, PhD
Yale Cancer Center
New Haven, CT

New targets in myeloid cells
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Rationale for combination therapies (including pre-clinical data)

Triple Negative Breast Cancer
Moderator: Rebecca Dent, MD, MSc
SingHealth, National Cancer Centre
Singapore

Deconstructing TNBC
Rebecca Dent, MD, MSc
SingHealth, National Cancer Centre
Singapore
Neoadjuvant/adjuvant TNBC (who doesn't need treatment/which adjuvant chemo/when and if to use platinum and IO)
Metastatic TNBC (non-IO- >PARP, ADCs, AKT)
IO and toxicities

"Choosing Wisely" to Reduce the Toxicity and Burden of Radiation Therapy
Moderator: Wendy Woodward, MD, PhD
UT MD Anderson Cancer Center
Houston, TX

Omitting radiotherapy in select situations
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Hypofractionated radiotherapy and emerging RT approaches
Jean L. Wright, MD
Johns Hopkins Medicine
Baltimore, MD

Strategies to reduce cardiac toxicity
Rachel B. Jimenez, MD
Massachusetts General Hospital
Boston, MA

SABCS with the Society of Surgical Oncology present De-escalation of Surgical Therapy: What Does the Data Support
Moderator: Eleftherios (Terry) Mamounas, MD, MPH
Orlando Health
Orlando, FL

DCIS
Pro
E. Shelley Hwang, MD, MPH
Duke University
Durham, NC

Con
Sarah McLaughlin, MD
Mayo Clinic
Jacksonville, FL


Exceptional responders to neoadjuvant chemotherapy
Pro
Joerg Heil, MD, PhD
University Hospital Heidelberg
Heidelberg, Germany

Con
Monica Morrow, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Metastasis - A Moving Target
Moderator: Suzanne AW Fuqua, PhD
Baylor College of Medicine
Houston, TX

Evolution and heterogeneity
Andrea Bild, PhD
City of Hope Comprehensive Cancer Center
Duarte, CA

EMT
Jing Yang
University of California San Diego
San Diego, CA

Dormancy
Lewis Chodosh, MD, PhD
University of Pennsylvania
Philadelphia, PA

Tumor Inflammation (and Metastasis) 
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Tumor INF signaling - A double edged sword in cancer
TBD

New insights to cancer-associated systemic inflammation
Karin de Visser, PhD
Netherlands Cancer Institute
Amsterdam, Netherlands

Obesity, inflammation and breast cancer - what's new
Pamela Goodwin,  MD
Mount SInai Hospital
Toronto, Canada

Genomic and Epigenomic Alterations in Resistance 

Chromosomal instability and tumor immunity
Mathieu Lupien, PhD
Princess Margaret Cancer Centre
Toronto, Canada

Epigenetic modifications: drug resistance and metastasis

Targeting adaptive resistance

Personalized HER2 Targeted Therapy 2020 - Are We There?
Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

HER2 targeted therapy: Determinates of response and mechanisms of resistance
Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Personalized treatment for early stage HER2-positive breast cancer
Aleix Prat, MD, PhD
Hospital Clinic I Provincial De Barcelona
Barcelona, Spain

Treatment of HER2-positive metastatic breast cancer - advances and challenges
Nancy Lin, MD
Dana-Farber Cancer Institute
Boston, MA

DNA Damage Repair
Moderator: Andrea Richardson, MD, PhD
Johns Hopkins Medicine
Washington, DC

Rescue DNA repair pathway and tumor immunity
Manjeet Rao, PhD
UT Health San Antonio
San Antonio, TX

DNA repair defect as a driver of therapy resistance
Serena Nik-Zainal, MD, PhD
University of Cambridge
Cambridge, United Kingdom

Targeting DDR
Simon Boulton, PhD
The Francis Crick Institute
London, United Kingdom

The Disparity Crisis in Breast Cancer

Tumor biology by race and ethnicity
Population based trends
Treatment difference and impact factors
 

Accelerating Recovery After Breast Cancer

Toxicities from therapies (including AIs, irreversible toxicities with IO, cardiotoxicity)
Facilitating the path to recovery (body image, sexuality, PROs)
Oncofertility (including PGD and insurance coverage)

Top

 



 

William L. McGuire Memorial Lecture

AACR Distinguished Lectureship in Breast Cancer Research

AACR Outstanding Investigator Award for Breast Cancer Research, funded by the Breast Cancer Research Foundation

Susan G. Komen® Brinker Awards

Top



Presented by SABCS and SSO Local Regional Management Following Neoadjuvant Therapy: Minding the Knowledge Gaps
Elizabeth A. Mittendorf, MD, PhD
Brigham and Women's Hospital
Boston, MA

Is There a Future for Cooperative Group Trials?
Norman E. "Ned" Sharpless, MD
National Cancer Institute
Bethesda, MD

Top



Recent Advances in Breast Cancer Prevention 

Does it have to hurt? Exercise, diet, and other lifestyle interventions
What else is in the imaging: How AI can improve mammograms?
Beyond hormones: Newer pharmacologic approaches

Mechanisms of Mutagenesis in Breast Cancer
Moderator: Douglas Yee, MD
University of Minnesota
Minneapolis, MN

Aging
Mike Stratton, FMedSci, FRS
Wellcome Sanger Institute
Hinxton, United Kingdom

BRCA/HRD
Andrew Tutt, MB CHB, PhD
Institute of Cancer Research
London, United Kingdom

APOBEC
Reuben Harris, PhD
University of Minnesota
Minneapolis, MN

Top





 


Saturday, December 12, 2020

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Dan L. Duncan Comprehensive Cancer Center
Houston, TX

Basic science

Translational research
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Early breast cancer   
Erika Hamilton, MD
Sara Cannon Research Institute
Nashville, TN

Advanced breast cancer
Rebecca Dent, MD, MSc
SingHealth, National Cancer Centre
Singapore

Top
 



The Tumor and Immune Ecosystem of Breast Cancer
Moderator: Chonghui Cheng, MD, PhD
Baylor College of Medicine
Houston, TX

Single-cell pathology landscape
TBD

Spatial variance signatures/Intra-tumor zonation in TNBC
Morag Park, PhD
Goodman Cancer Research Centre
Montrea, Canada

Top



Antibody-Drug Conjugates, Better Together 
Mark Pegram, MD
Stanford University
Stanford, CA

The making of an ADC
Paul Parren, PhD
Lava Therapeutics
Utrecht, Netherlands

What's available now and what's on the horizon (Early development)
Aditya Bardia, MBBS, MPH
Massachusetts General Hospital
Boston, MA

Mechanisms of Response to Immune Checkpoint Therapies
Moderator: Jeffrey Rosen, PhD
Baylor College of Medicine
Houston, TX

B-cells and follicular T cells regulate responses to ICT in hypermutated tumors
Charles Perou, PhD
University of North Carolina
Chapel Hill, NC 

DNA replicative stress regulates responses to ICT in non-hypermutated tumors
Shiaw-Yih (Phoebus) Lin, PhD
UT MD Anderson Cancer Center
Houston, TX

Top



Next Generation Sequencing in Clinical Practice

Understanding current platforms
Interpreting reports

Top



Molecular Biology in Breast Oncology
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Single cell technology (including sequencing and imaging)
Patient derived organoids

Clinical Research Workshop
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

Research technology for clinicians (CTCs, cfDNA, Crispr)
Nicholas Turner, PhD, FRCP, BM, MA
The Royal Marsden Hospital
London, United Kingdom

Capturing patient reported outcomes

Improving clinical trial design
Thomas Braun, PhD
University of Michigan
Ann Arbor, MI

Increasing clinical trial accrual
Deborah Collyar
Patient Advocates in Research (PAIR)
San Francisco, CA

Top



                                                                                                                       

Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX                                                                                                                           



CAREER DEVELOPMENT FORUMNETWORKING SESSION FOR YOUNG INVESTIGATORS

                                                                                                                       

The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the 2020 SABCS. Space in the workshop is limited. Preregistration is not required.                                                                                                                             


SPECIAL SESSION

Global Breast Cancer Screening

Clinical Research Workshop
Moderator: Ismail Jatoi, MD
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

      Breast cancer screening trials in low and middle income countries:  Lessons learned
Rengaswamy Sankaranarayanan, MD, MBBS
RTI International
New Delhi, India

Weighing the benefits and harms of breast cancer
screening

Phillippe Autier, MD, MPH
International Prevention Research Institute
Lyon, France



All Breast Cancer Patients Should Have Germline Genetic Testing
Chairman: Virginia Kaklamani, MD
UT Health San Antonio MD Anderson Cancer Center
San Antonio, TX

 

Friday, December 11, 2020


        Moderator: Steve Vogl, MD
        Scarsdale, NY

        Panel Members

        Peter Dubsky, MD
        Hirslanden Klinik St Anna
        Luzern, Switzerland

        William Gradishar, MD, FASCO, FACP
        Northwestern University
        Chicago, IL

        Alice Ho, MD
        Massachusetts General Hospital
        Boston, MA

        Christine Hodgdon
        Patient Advocate
        Baltimore, MD

        Sara Hurvitz, MD
        UCLA
        Santa Monica, CA

        Martine Piccart, MD, PhD
        Institut Jules Bordet
        Brussels, Belgium

        Meredith Regan, SCD
        Dana-Farber Cancer Institute
        Boston, MA


PRELIMINARY SCHEDULE


Hours subject to change




Monday, December 7  Registration  12:00 PM - 5:00 PM 
Tuesday, December 8  Registration  8:00 AM - 7:00 PM ;
  Program (Workshops and Educational Sessions)  11:45 AM - 7:00 PM 
Wednesday, December 9  Registration  7:00 AM - 5:15 PM 
  Program (Main Program begins)  8:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 
Thursday, December 10  Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 7:00 PM 
  Exhibits  10:00 AM - 5:00 PM 
Friday, December 11  Registration  6:45 AM - 5:15 PM 
  Program  7:00 AM - 7:30 PM 
  Exhibits  10:00 AM - 5:00 PM 
Saturday, December 12  Registration  6:45 AM - 9:00 AM 
  Program  7:00 AM - 11:00 AM 

Top
In collaboration with  Astro     and     SSO